Administrative information
Title {1} | Oral nicotinamide mononucleotide (NMN) as a treatment for chronic insomnia: protocol for the multicenter, randomized, double-blind, placebo-controlled trial |
---|---|
Trial registration {2a and 2b} | Chinese Clinical Trial Registry (chictr.org.cn): ChiCTR2200058001. Registered on 26 March 2022. ChiCTR2200058001 |
Protocol version {3} | 13 March 2022. Version 1 |
Funding {4} | This trial is funded by grants from China Health Promotion Foundation |
Author details {5a} | Xiangyang Gao, Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China Junhua Li, Health Management Center, Handan Central Hospital, Handan, Hebei Province, China Sanping Xu, Health Management Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province China Xueying Li, Department of Biostatistics, Peking University First Hospital, Beijing 100,034, China Xicheng Wang, Beijing Dublin International Collage, Beijing University of Technology, Beijing 100,124, China Yongli Li, Health Management Center, Henan Provincial People's Hospital, Zhengzhou, China Yan Huang, Health Management Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China Shaohui Liu, Health Management Center, Xiangya Hospital, Central South Hospital, Changsha, Hunan Province, China Qiang Zeng, Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China XYG and ZQ are the Chief Investigators who conceived the study, led the proposal and protocol development. JHL, SPX, XYL, XCW, YLL, SHL, and HY all contributed to the trial design and to development of the proposal. XYL and XCW are lead trial methodologist. All authors read and approved the final protocal manuscript |
Name and contact information for the trial sponsor {5b} | This trial is funded and proceeded by China Health Promotion Foundation Wu Shiyong, Room 521,Wankai Road, Fentai District, Beijing, China, + 86–13,261,008,988, Email: 82,125,586@qq.com |
Role of sponsor {5c} | This trial is solely funded by non-commercial sources. Funding sources have had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results |
Data category | Information |
---|---|
Primary registry and trial identifying number | ChiCTR2200058001 |
Date of registration in primary registry | March 26, 2022 |
Secondary identifying numbers | NA |
Source(s) of monetary or material support | China Health Promotion Foundation |
Primary sponsor | China Health Promotion Foundation |
Secondary sponsor(s) | NA |
Contact for public queries | Wu Shiyong (Email: 82,125,586@qq.com) |
Contact for scientific queries | Qiang Zeng, MD (Email: zq301@126.com) |
Public title | Oral nicotinamide mononucleotide (NMN) as a treatment for chronic insomnia: protocol for the multicenter, randomized, double-blind, placebo-controlled trial |
Scientific title | Oral nicotinamide mononucleotide (NMN) as a treatment for chronic insomnia: protocol for the multicenter, randomized, double-blind, placebo-controlled trial |
Countries of recruitment | China |
Health condition(s) or problem(s) studied | Chronic insomnia |
Intervention(s) | Active comparator: Nicotinamide mononucleotide (320 mg/day) Placebo comparator: Placebo |
Key inclusion and exclusion criteria | Inclusion criteria: Age between 18 and 65 years; clinical diagnosis of chronic insomnia (according to the ICSD-3 criteria for chronic insomnia) |
Exclusion criteria: Physical diseases, mental disorders, and/or sleep disorders; received any insomnia drugs and psychotherapy within the preceding 1 month; on a continuous current daily intake of nutritional supplements and vitamin supplements | |
Study type | Interventional |
Multicenter, double-blinded, randomized controlled superiority trial with a two-group parallel design | |
Phase III | |
Date of first enrolment | April 2022 |
Target sample size | 400 |
Recruitment status | Recruiting |
Primary outcome(s) | Pittsburgh Sleep Quality Index (PSQI) |
Key secondary outcomes | Epworth Sleeping Scale (ESS), Insomnia Severity Index (ISI), Total sleep time (TST), sleep efficiency (SE), sleep latency, REM sleep latency, the percentage of N1, N2, N3, and REM |
Introduction
Background and rationale {6a}
Insomnia
Objectives {7}
Trial design {8}
Methods: participants, interventions, and outcomes
Study setting {9}
Eligibility criteria {10}
Inclusion criteria
Exclusion criteria
Who will take informed consent? {26a}
Additional consent provisions for collection and use of participant data and biological specimens {26b}
Interventions
Explanation for the choice of comparators {6b}
Intervention description {11a}
Criteria for discontinuing or modifying allocated interventions {11b}
-
Allergic reactions: If allergic skin reactions have been observed, discontinue allocated interventions. Meanwhile, this should be reported as an adverse event.
-
Headache: If headache has been observed, temporary suspension of the allocated intervention until the symptom disappears is recommended. If the headache re-happens, discontinue allocated interventions. Meanwhile, this should be reported as an adverse event.
-
Nausea: If nausea has been observed, temporary suspension of the allocated intervention until the symptom disappears is recommended. If the headache re-happens, discontinue allocated interventions. Meanwhile, this should be reported as an adverse event.
Strategies to improve adherence to interventions {11c}
Relevant concomitant care permitted or prohibited during the trial {11d}
Provisions for post-trial care {30}
Outcomes {12}
Primary outcome
Secondary outcome
Safety outcome
Participant timeline {13}
Sample size {14}
Recruitment {15}
Assignment of interventions: allocation
Sequence generation {16a}
Concealment mechanism {16b}
Implementation {16c}
Assignment of interventions: blinding who will be blinded {17a}
Procedure for unblinding if needed {17b}
Data collection and management
Plans for assessment and collection of outcomes {18a}
Plans to promote participant retention and complete follow-up {18b}
Data management {19}
Confidentiality {27}
Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}
Statistical methods
Statistical methods for primary and secondary outcomes {20a}
Interim analyses {21b}
Methods for additional analyses (e.g., subgroup analyses) {20b}
Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}
Plans to give access to the full protocol, participant-level data and statistical code {31c}
Oversight and monitoring
Composition of the coordinating center and trial steering committee {5d}
Composition of the data monitoring committee, its role and reporting structure {21a}
Refer to above {5d}
Adverse event reporting and harms {22}
Frequency and plans for auditing trial conduct {23}
Plans for communicating important protocol amendments to relevant parties (e.g., trial participants, ethical committees) {25}
Dissemination plans {31a}
Discussion
-
The use of a randomization scheme with allocation concealment and double blinding.
-
The use of a placebo similar in appearance and taste to the treatment.
-
A comprehensive assessment for sleep efficiency.